Viemed Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
The presentation highlighted robust organic growth, expanding service lines, and disciplined acquisitions, supported by a strong balance sheet and regulatory tailwinds. Diversification into sleep and maternal health is driving revenue, while operational efficiencies and technology underpin margin improvements and scalability.
-
Record Q2 revenue and patient growth were driven by strong performance in ventilation, sleep, and maternal health. Guidance for full-year revenue and EBITDA was raised, with ongoing investments in technology and sales capacity supporting future growth.
-
Revenue grew 28% year-over-year to $75.4 million, with strong gains in sleep, maternal health, and ventilation. Free cash flow improved by $8.3 million, and guidance for 2026 was raised, reflecting operational momentum and capital efficiency.
-
Home-based care platform continues rapid, profitable growth through service diversification, technology, and disciplined M&A. Regulatory clarity and favorable reimbursement trends support expansion, with strong momentum in sleep, maternal health, and staffing divisions.
-
The company has evolved from a ventilator-focused provider to a diversified home healthcare leader, leveraging clinical data, technology, and a unique sales model to drive organic and acquisitive growth. Recurring revenue is strong, margins are stable, and future growth will focus on expanding complex respiratory and maternal health services.
Fiscal Year 2025
-
Record revenue and Adjusted EBITDA were achieved in 2025, driven by strong growth in sleep and maternal health, with free cash flow more than doubling year-over-year. 2026 guidance projects 17% revenue growth and stable margins, supported by a diversified platform and robust capital allocation.
-
Record revenue and strong growth across diversified service lines, with sleep and maternal health segments accelerating and the Lehans acquisition boosting scale. Guidance narrowed with improved EBITDA margin outlook, while disciplined capital allocation and innovation drive operational efficiency.
-
Focused on complex respiratory and sleep therapy, the company has achieved consistent organic growth, expanding its product mix and geographic reach while maintaining profitability. Recent acquisitions and technology investments support a resilient, scalable model and strong clinical outcomes.
-
Q2 2025 saw 14.7% revenue growth, driven by organic expansion and strong performance in core ventilation, sleep therapy, and resupply. Guidance for 2025 was raised following the Lehan acquisition, with continued margin improvement and robust liquidity supporting growth.
-
A national in-home respiratory care provider reported strong organic growth, expanding through targeted acquisitions and technology integration. Financial performance remains robust, with double-digit revenue and net income growth, a new share buyback, and continued focus on underserved markets.
-
Q1 results surpassed expectations with 16.9% revenue growth and a 26% rise in adjusted EBITDA. Guidance for 2025 was raised, and the Lehan acquisition is set to expand market reach and diversify offerings. No net debt and strong free cash flow position support continued growth.
Fiscal Year 2024
-
Record revenue and patient growth in 2024 were driven by strong vent and sleep segments, with adjusted EBITDA up 19% year-over-year. 2025 guidance projects 16% revenue growth and 10% adjusted EBITDA growth, supported by a robust balance sheet and expanding behavioral health services.
-
Record Q3 revenue of $58M was driven by strong organic growth and operational improvements, with EBITDA margin rising to 24.1%. Vent and sleep segments both saw robust patient growth, and Q4 guidance projects continued double-digit revenue increases.
-
Record Q2 revenue of $55M marked a 27% year-over-year increase, driven by strong organic growth, sales force restructuring, and successful integration of acquisitions. Gross and EBITDA margins remained robust, and guidance points to continued double-digit growth in Q3.